AlloVir Gains PRIME Status For Anti-Virus T-Cell Therapy
Led By Ex-Alexion CEO David Hallal
Executive SummaryJoining the ElevateBio stable last May, the company has now gained priority status in the US and Europe for its novel therapy for viral infections in stem cell transplant patients.
You may also be interested in...
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.